291 results on '"den Hartog, Gerco"'
Search Results
2. Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands
3. Effect of age and season on respiratory mucosal immune marker profiles
4. Exploring host-commensal-pathogen dynamics in cell line and organotypic human intestinal epithelial models
5. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
6. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
7. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
8. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
9. Apurinic/Apyrimidinic Endonuclease 1 Restricts the Internalization of Bacteria Into Human Intestinal Epithelial Cells Through the Inhibition of Rac1.
10. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
11. The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years
12. SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
13. Prevalence of human respiratory pathogens and associated mucosal cytokine levels in young children and adults: a cross-sectional observational study in the Netherlands during the winter of 2012/2013
14. SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics
15. Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort
16. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
17. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
18. Serological profiling of pneumococcal proteins reveals unique patterns of acquisition, maintenance and waning of antibodies throughout life
19. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
20. Circulation of Bordetella pertussis in the Caribbean Netherlands: a population-based seroepidemiological study
21. Oxidative Stress Resulting From Helicobacter pylori Infection Contributes to Gastric Carcinogenesis.
22. Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands
23. IgG1 glycosylation highlights premature aging in Down syndrome.
24. Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study.
25. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
26. Regulation of Rac1 and Reactive Oxygen Species Production in Response to Infection of Gastrointestinal Epithelia.
27. Effect of age and season on respiratory mucosal immune marker profiles
28. Nationwide SARS-CoV-2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era, 2021-2022: an Ongoing Prospective Cohort Study
29. Ecological interactions between host, commensal and pathogenic bacteria in models for the intestinal epithelium.
30. P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
31. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
32. Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines
33. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
34. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
35. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI):a cohort study
36. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
37. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
38. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
39. Gut Barrier: Innate Immunity
40. Contributors
41. Age‐specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands.
42. A Novel Hypomorphic Apex1 Mouse Model Implicates Apurinic/Apyrimidinic Endonuclease 1 in Oxidative DNA Damage Repair in Gastric Epithelial Cells
43. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies
44. Decline of RSV-specific antibodies during the COVID-19 pandemic
45. Decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with Down syndrom
46. Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study
47. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
48. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
49. Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
50. Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.